981 related articles for article (PubMed ID: 26720853)
61. Prescription drug spending for Medicare+Choice beneficiaries in the last year of life.
Fahlman C; Lynn J; Doberman D; Gabel J; Finch M
J Palliat Med; 2006 Aug; 9(4):884-93. PubMed ID: 16910803
[TBL] [Abstract][Full Text] [Related]
62. Association of Medicare Part D Benzodiazepine Coverage Expansion With Changes in Fall-Related Injuries and Overdoses Among Medicare Advantage Beneficiaries.
Maust DT; Lin LA; Goldstick JE; Haffajee RL; Brownlee R; Bohnert ASB
JAMA Netw Open; 2020 Apr; 3(4):e202051. PubMed ID: 32242907
[TBL] [Abstract][Full Text] [Related]
63. Out-of-Pocket Spending and Premium Contributions After Implementation of the Affordable Care Act.
Goldman AL; Woolhandler S; Himmelstein DU; Bor DH; McCormick D
JAMA Intern Med; 2018 Mar; 178(3):347-355. PubMed ID: 29356828
[TBL] [Abstract][Full Text] [Related]
64. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D.
Madden JM; Graves AJ; Zhang F; Adams AS; Briesacher BA; Ross-Degnan D; Gurwitz JH; Pierre-Jacques M; Safran DG; Adler GS; Soumerai SB
JAMA; 2008 Apr; 299(16):1922-8. PubMed ID: 18430911
[TBL] [Abstract][Full Text] [Related]
65. Regulations regarding income-related monthly adjustment amounts to Medicare beneficiaries' prescription drug coverage premiums. Final rule.
Social Security Administration
Fed Regist; 2012 Jul; 77(143):43496-8. PubMed ID: 22834072
[TBL] [Abstract][Full Text] [Related]
66. Falling into the coverage gap: Part D drug costs and adherence for Medicare Advantage prescription drug plan beneficiaries with diabetes.
Fung V; Mangione CM; Huang J; Turk N; Quiter ES; Schmittdiel JA; Hsu J
Health Serv Res; 2010 Apr; 45(2):355-75. PubMed ID: 20050931
[TBL] [Abstract][Full Text] [Related]
67. Promoting access and reducing expected out-of-pocket prescription drug costs for vulnerable Medicare beneficiaries: a pharmacist-directed model.
Cutler TW; Stebbins MR; Smith AR; Patel RA; Lipton HL
Med Care; 2011 Apr; 49(4):343-7. PubMed ID: 21407030
[TBL] [Abstract][Full Text] [Related]
68. Part D plan enrollment by uninsured medicare beneficiaries.
Maciejewski ML; Farley JF; Hansen RA; Wei D; Harman JS
Med Care; 2010 Feb; 48(2):183-6. PubMed ID: 20057332
[TBL] [Abstract][Full Text] [Related]
69. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
Centers for Medicare & Medicaid Services (CMS), HHS
Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
[TBL] [Abstract][Full Text] [Related]
70. Medicare Part D roulette: potential implications of random assignment and plan restrictions.
Patel RA; Walberg MP; Woelfel JA; Amaral MM; Varu P
Medicare Medicaid Res Rev; 2013; 3(2):. PubMed ID: 24753963
[TBL] [Abstract][Full Text] [Related]
71. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap.
Polinski JM; Shrank WH; Huskamp HA; Glynn RJ; Liberman JN; Schneeweiss S
PLoS Med; 2011 Aug; 8(8):e1001075. PubMed ID: 21857811
[TBL] [Abstract][Full Text] [Related]
72. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
73. Out-of-pocket health expenses for Medicaid and other poor and near-poor persons in 1980.
Howell E; Corder L; Dobson A
Natl Med Care Util Expend Surv B; 1985 Aug; (4):1-52. PubMed ID: 10313450
[TBL] [Abstract][Full Text] [Related]
74. Unfilled Prescriptions of Medicare Beneficiaries: Prevalence, Reasons, and Types of Medicines Prescribed.
Kennedy J; Tuleu I; Mackay K
J Manag Care Spec Pharm; 2020 Aug; 26(8):935-942. PubMed ID: 32715958
[TBL] [Abstract][Full Text] [Related]
75. The Medicare Part D doughnut hole: effect on pharmacy utilization.
Sun SX; Lee KY
Manag Care Interface; 2007 Sep; 20(9):51-5, 59. PubMed ID: 18161394
[TBL] [Abstract][Full Text] [Related]
76. Cancer history, insurance coverage, and cost-related medication nonadherence in Medicare beneficiaries, 2013-2018.
Li M; Bounthavong M
J Manag Care Spec Pharm; 2021 Dec; 27(12):1750-1756. PubMed ID: 34818087
[No Abstract] [Full Text] [Related]
77. Understanding the Medicare Part D prescription program: partnerships for beneficiaries and health care professionals.
De Natale ML
Policy Polit Nurs Pract; 2007 Aug; 8(3):170-81. PubMed ID: 18178923
[TBL] [Abstract][Full Text] [Related]
78. Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance Programs.
Kang SY; Sen A; Bai G; Anderson GF
JAMA; 2019 Aug; 322(5):422-429. PubMed ID: 31386135
[TBL] [Abstract][Full Text] [Related]
79. Take-up of Medicare Part D: results from the Health and Retirement Study.
Levy H; Weir DR
J Gerontol B Psychol Sci Soc Sci; 2010 Jul; 65(4):492-501. PubMed ID: 20034992
[TBL] [Abstract][Full Text] [Related]
80. Benzodiazepine use and expenditures for Medicare beneficiaries and the implications of Medicare Part D exclusions.
Yang HW; Simoni-Wastila L; Zuckerman IH; Stuart B
Psychiatr Serv; 2008 Apr; 59(4):384-91. PubMed ID: 18378837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
